Evidence map›Paper›PMID 15887979›Full record

ArticleMolecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology2004

Retinoblastoma: genetic testing versus conventional clinical screening in India.

Biju Joseph, Mahesh Palanivelu Shanmugam, Madhuravasal Krishnan Srinivasan, Govindasamy Kumaramanickavel

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Mutational analysis of theFrontiers in medicine · 2024
    Article
  3. Article
  4. An Online Application for Retinoblastoma Surveillance.Ocular oncology and pathology · 2020
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Biju JosephSN ONGC, Department of Genetics and Molecular Biology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Mahesh Palanivelu Shanmugam
Madhuravasal Krishnan Srinivasan
Govindasamy Kumaramanickavel
Sankara Nethralaya · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGenetic testing is increasingly being used to evaluate susceptibility to hereditary diseases because it is a cost effective screening method. Predictive testing for retinoblastoma can help to save the vision and avoid unnecessary (and invasive) eye examinations for probands and their close relatives. This study was undertaken to evaluate the cost effectiveness of the retinoblastoma genetic screening strategy established in our hospital. STUDY

designCytogenetic study of peripheral blood, mutational, and methylation analyses from the tumor DNA of 25 patients with retinoblastoma was undertaken. The cost for retinoblastoma (RB1) gene screening was calculated based on the cost of the chemicals and consumables used and the clinical examination charges at our hospital. A comparison was made between the cost of genetic screening and clinical testing for retinoblastoma. Retinoblastoma patients underwent clinical management and genetic testing at Sankara Nethralaya, Chennai, India.

resultsBy adopting a genetic screening strategy, a 3.5-fold cost saving was seen for a proband while a 6-fold saving was seen for a family with two sibs compared to the cost of clinical examination. The clinical examination fee and cost of genetic screening for a proband was dollarUS536 and dollarUS152, respectively, while for a nuclear family with two sibs the costs were dollarUS1071 and dollarUS175, respectively. DISCUSSION: Savings for a family will be higher if indirect costs, such as savings in travel times to and from the hospital and labor savings, were taken into account. Cost will be a major factor in determining the implementation of genetic screening for RB1 gene in the clinical practice.

conclusionIn our study in India, genetic screening for retinoblastoma was cheaper than conventional screening and was useful in the genetic counseling of the families.

Indexed as

Child, PreschoolCost-Benefit AnalysisDiagnostic Techniques, OphthalmologicalGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansIndiaPedigreeRetinal NeoplasmsRetinoblastomaRetinoblastoma ProteinRetinoblastoma Protein

Identifiers

PMID15887979
OpenAlexW1990121456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.